{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"7","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Time to radiologic disease progression or death","dispersionType":"95% Confidence Interval","groups":[{"description":"The study drugs will be administered in the following manner: Gemcitabine, at 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin, at 100 mg/m² IV infusion over 2 hours.","id":"OG000","title":"Oxaliplatin and Gemcitabine"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"50 months","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}